First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

Author： Leon Luis   Vázquez Sergio   Gracia José Manuel   Casal Joaquín   Lazaro Martín   Firvida José Luis   Amenedo Margarita   Santome Lucia   Macia Sonia  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.10, 2012-07, pp. : 1389-1396

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer: A Brazilian Center Experience

By >   >   >   >   Katz Artur  

Drugs in R&D, Vol. 12, Iss. 4, 2012-12 ,pp. : 207-216

Adis International

Access to resources Recommend Favorite

Bevacizumab in Non-Small Cell Lung Cancer

By Francesco Di Costanzo  

Drugs, Vol. 68, Iss. 6, 2008-01 ,pp. : 737-746

Adis International

Access to resources Recommend Favorite

Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: Results of a prospective randomized phase II study

By Esteban Emilio   Fra Joaquin   Fernández Yolanda   Corral Norberto   Vieitez José   Palacio Isabel   Sande José   Fernández José   Muñiz Isabel   Villanueva Noemi   Estrada Enrique   Mareque Beatriz   Uña Esther   Buesa José   Lacave Angel  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 241-248

Springer Publishing Company

Access to resources Recommend Favorite

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer

By Doebele Robert C.   Spigel David   Tehfe Mustapha   Thomas Sachdev   Reck Martin   Verma Sunil   Eakle Janice   Bustin Frederique   Goldschmidt Jerome   Cao Dachuang   Alexandris Ekaterine   Yurasov Sergey   Camidge D. Ross   Bonomi Philip  

Cancer, Vol. 121, Iss. 6, 2015-03 ,pp. : 883-892

Blackwell Publishing

Access to resources Recommend Favorite

Bowel perforation in non-small cell lung cancer after bevacizumab therapy

By Schellhaas Elisabeth   Loddenkemper Christoph   Schmittel Alexander   Buhr Heinz-J.   Pohlen Uwe  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 184-187

Springer Publishing Company

Access to resources Recommend Favorite